Business Context and Reporting Period
This Form 8-K Current Report was filed by American BriVision (Holding) Corporation on July 12, 2019, regarding events occurring on June 30, 2019. The filing discloses the entry into a Material Definitive Agreement and the unregistered sale of securities involving a related party transaction.
Key Financial Metrics and Transaction Details
The filing details a specific debt-for-equity transaction rather than standard operating financial metrics. The Company issued 428,571 shares of common stock to BioFirst Corporation to settle an outstanding debt obligation of $3,000,000. This transaction relates to a collaborative agreement dated July 24, 2017, concerning the global licensing rights to co-develop BFC-1401 (ABV-1701) Vitreous Substitute for Vitrectomy. The filing text does not provide clear values for revenue, profit, cash flow, margins, or overall liquidity positions outside of this specific transaction.
Material Changes Versus Prior Period
The primary material change reported is the conversion of a $3,000,000 liability owed to BioFirst Corporation into equity. This transaction reduces the Company's debt to this related party to zero and increases the outstanding share count by 428,571 shares. No other material changes in financial condition or operations are disclosed in this specific report.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future outlook, or specific risk factors beyond the disclosure of the related party nature of the transaction. The issuance of shares was made in reliance on the exemption from registration pursuant to Section 4(a)(2) under the Securities Act of 1933. The transaction involves BioFirst Corporation, which is a related party as it is under common control with Yuangene Corporation, the Company's controlling shareholder.
Important Facts for Investor Verification
- Verify the impact of the 428,571 new shares on total outstanding shares and potential dilution.
- Confirm the status of the $3,000,000 debt settlement and its effect on the Company's balance sheet liabilities.
- Review the full text of the Stock Purchase Agreement (Exhibit 10.1) for additional covenants or conditions.
- Assess the development status of the BFC-1401/ABV-1701 Vitreous Substitute, which is the underlying asset for the original debt obligation.
- Confirm the related party relationship between BioFirst Corporation and the Company's controlling shareholder, Yuangene Corporation.